Navigation Links
Valensa Completes Second Expansion of Astaxanthin Capacity
Date:4/14/2009

"Made in USA" label and allergen-free status of extracted product driving demand

ORLANDO, Fla., April 14 /PRNewswire/ -- Valensa International announced that it has completed a second round of expansion for astaxanthin production at its Eustis, Florida facility. The move was made in light of growing demand for a high-quality astaxanthin from North America that is both pesticide-free and allergen-free -- two conditions that are only possible with carefully controlled raw material monitoring and extraction facilities that are not used for extractions of materials that are known to cause allergic reactions, such as legumes and shellfish. The company announced a 20% expansion of capacity in February 2008. With the new capacity, Valensa is now producing 40% more of its ZANTHIN(R) natural astaxanthin extract than it did in 2007.

According to Dr. Rudi E. Moerck, President and CEO of Valensa, the recent expansions have come as a result of rapidly increasing demand in Europe for astaxanthin for eye health formulations, but have also been fueled by European and U.S.-based companies needing to establish a clear country of origin for their astaxanthin products as well as assuage concerns about potential contamination by allergenic materials. "Right now, Valensa International is the only company in the market who manufactures -- or extracts -- astaxanthin oleoresin in the United States. As a fully integrated supplier of astaxanthin, our customers can rely on where their product gets made," Moerck said. "When marketers of natural astaxanthin contract out for the extraction of biomass to produce natural astaxanthin, there is a chance that the extracting company will process multiple raw materials through the same facilities. We have seen instances in the market where materials such as shellfish are produced in the same facilities as astaxanthin and are sold without appropriate label warnings introducing the possibility of allergenicity into the final astaxanthin extract. Companies who work with Valensa are assured that cross-contamination of this type does not exist, and as a result, have chosen a fully integrated solution from sourcing algae biomass, to CO2 extraction and standardization," he added.

Made in the USA

Valensa's ZANTHIN(R) natural astaxanthin is an ultra-high pressure supercritical CO2 extraction of Haematococcus pluvialis freshwater algae that uses no chemical solvents. Valensa is the only fully integrated supplier of natural astaxanthin extract in the U.S. It is made to cGMP standards in a certified organic facility in Florida and the product is protected with Valensa's all-natural, proprietary O2B(R) stabilization technology which provides extra stability in storage, efficacy and in customer's formulations. Valensa's approach to manufacturing ensures the highest-quality, most consistent product on the market -- and recommends it for eye health and for its potent anti-oxidant properties.

"Quality is critical to the acceptance of astaxanthin in all product formulations especially eye health formulas. At Valensa, we are committed to providing the highest-quality astaxanthin on the market," said Moerck.

    For further information, contact:

    Dr. Rudi Moerck, President and CEO
    Voice: 352-357-2004 ext. 701
    Fax: 352-483-2095

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Valensa International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Valensa Internationals Dr. Rudi E. Moerck Appointed CEO
2. Valensa International and Parry Nutraceuticals Join Forces in the Global Natural Products Marketplace
3. Valensa and Parry Nutraceuticals Introduce Organic SpiruZan(TM) Spirulina/Astaxanthin Complex as Lifestyle Support for a Fast-Paced World
4. Pacer Health Corporation Successfully Completes Assignment of $11.7 Million in Convertible Debentures
5. Metropolitan Nashville Hospital Authority Completes Voice and Data Upgrade with tw telecoms Network Solutions
6. Aegis Living Completes Purchase of Real Estate in Aptos
7. AMICAS Successfully Completes Tender Offer for Shares of Emageon Inc.
8. DST Systems, Inc. Completes Acquisition of Remaining 50% of Argus Health Systems, Inc.
9. Insmed Completes Sale of Follow-On Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Immunotech Completes Merger Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... California Senate ... medical payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ ... Research Institute (WCRI) . , According to the study, medical payments per claim in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael ... headquartered in Hamilton County, is embarking on a charity drive with the aim ... new homes for orphaned or neglected senior dogs in the Cincinnati region, and ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
(Date:12/7/2016)... Wisconsin (PRWEB) , ... December 07, 2016 , ... Kenall ... extraordinary new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire ... right amount of light where and when it’s needed. , A 2’ ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... (“Presence”) for a purchase price of approximately $17.4 million (net of the ... revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is a ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... N.J., Dec. 8, 2016 CANTEL MEDICAL CORP. (NYSE: ... of $18,800,000, or $0.45 per diluted share, on a 22.1% ... quarter ended October 31, 2016. This compares with net income ... $153,779,000 for the first quarter ended October 31, 2015. ... quarter ended October 31, 2016 to $21,323,000, or $0.51 per ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire/ ... with cutting edge next-generation sequencing and bioinformatics expertise; AITbiotech Pte ... the Genome Institute of Singapore (GIS) ... joint venture between Novogene and AITbiotech – will establish a ... Singapore .   The new centre will ...
(Date:12/7/2016)... Dec. 7, 2016   IQuity, Inc., a ... Don Hardison has been appointed to ... executive with extensive experience as CEO, COO, and ... 500 companies within the molecular, clinical diagnostic, and ... and sales experience within the pharmaceutical industry. His ...
Breaking Medicine Technology: